TP53 and neoplasm: ABE-edited CAR-T cells showed higher manufacturing yields, superior in vitro effector functions under continuous antigen stimulation, reduced activation of p53 and DNA damage response pathways at baseline, improved tumor control, and extended overall survival compared to their Cas9-edited counterparts.